246 related articles for article (PubMed ID: 21861801)
1. Therapy for non-clear cell histologies in renal cancer.
Bitting RL; Madden J; Armstrong AJ
Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801
[TBL] [Abstract][Full Text] [Related]
2. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
3. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
4. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
5. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Bellmunt J; Dutcher J
Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
[TBL] [Abstract][Full Text] [Related]
8. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development.
Rasmussen N; Rathmell WK
Curr Clin Pharmacol; 2011 Aug; 6(3):199-206. PubMed ID: 21470103
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
11. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.
Zhang T; Gong J; Maia MC; Pal SK
Am Soc Clin Oncol Educ Book; 2017; 37():337-342. PubMed ID: 28561708
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
14. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.
Ghatalia P; Zibelman MR; Geynisman DM; Plimack ER
Clin Adv Hematol Oncol; 2018 Oct; 16(10):677-686. PubMed ID: 30543598
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for non-clear-cell renal cell carcinoma.
David KA; Milowsky MI; Nanus DM
Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
[TBL] [Abstract][Full Text] [Related]
18. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
[TBL] [Abstract][Full Text] [Related]
19. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
20. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
